Integrated Cancer Research Site
Search
Actualité - Publications

Metastatic breast cancers : a new tool for treatment choice?

SIRIC team
11/24/2020
Partager
The first study showing that a biomarker can be used to guide first-line treatment choice in HER2 positive breast cancers
JAMA Oncology

Circulating tumoral cells (CTCs) are cells that have detached from the solid tumor and move around the body in the bloodstream. The number of CTCs in the blood is one of the prognostic markers for metastatic breast cancers including HER2+ breast cancer. 

Bidard et al ask the question: can the CTC count be used as a reliable, standardized and reproducible alternative to clinical evaluation as the basis for determining the first-line treatment choice for these cancers ?

In this article, the team presents the results of the randomized clinical trial STIC CTC initially set up to reply to this question, which confirms their hypothesis. CTCs could be a new tool for clinicians and have an impact on care. 

 

Abstract visuel de Bidard et al, JAMA Oncol, 2020
Contact
Our research program
Examen sein
Breast cancers

Breast cancer is the most common malignant tumor in women with around 50 000 new cases diagnosed each year in France…